Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AO-176 · 1 trial · 1 indication
Evaluate the safety of AO-176 measured by the number adverse events, serious adverse events and lab abnormalities.
Evaluate the safety of AO-176 in combination with paclitaxel measured by the number adverse events, serious adverse events and lab abnormalities.
Evaluate the safety of AO-176 in combination with pembrolizumab measured by the number adverse events, serious adverse events and lab abnormalities.
| Arm | Type | Description |
|---|---|---|
| AO-176 Dose Escalation | EXPERIMENTAL | Each dose escalation cohort will initially recruit 3 patients to receive AO-176 in a standard 3+3 design; cohorts will be expanded in the event of a DLT. |
| AO-176 Dose Expansion | EXPERIMENTAL | Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176. |
| AO-176 + Paclitaxel Dose Escalation | EXPERIMENTAL | Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and paclitaxel in a standard 3+3 design; cohorts will be expanded in the event of a DLT. |
| AO-176 + Paclitaxel Dose Expansion | EXPERIMENTAL | Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176 + paclitaxel. |
| AO-176 + Pembrolizumab Dose Escalation | EXPERIMENTAL | Each dose escalation cohort will initially recruit 3 patients to receive AO-176 and pembrolizumab in a standard 3+3 design; cohorts will be expanded in the event of a DLT. |
| AO-176 + Pembrolizumab Dose Expansion | EXPERIMENTAL | Once the MTD/RP2D has been established, tumor-specific dose expansion cohorts will be recruited to further assess safety and evaluate preliminary efficacy of AO-176 + pembrolizumab. |
| Name | Type | Description |
|---|---|---|
| AO-176 | DRUG | Humanized monoclonal antibody (mAb) targeting CD47 |
| AO-176 + Paclitaxel | DRUG | Humanized monoclonal antibody (mAb) targeting CD47 and paclitaxel |
| AO-176 + Pembrolizumab | DRUG | Humanized monoclonal antibody (mAb) targeting CD47 and pembrolizumab |
Key Inclusion Criteria 1. Select advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist, or is no longer effective Part A: * Epithelial ovarian carcinoma (EOC) * Endometrial carcinoma * Castration resistant prostate cancer * Non-small cell ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
AO-176 is an investigational small molecule being studied for the treatment of solid tumors. It is in Phase 1 clinical development for this oncology indication. The drug is not approved and remains under clinical investigation.
AO-176 is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company is conducting clinical research on this investigational oncology drug for solid tumors.
AO-176 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities.
AO-176 has one completed Phase 1 clinical trial, identified as NCT03834948, titled "AO-176 in Multiple Solid Tumor Malignancies." The study enrolled 57 participants in the United States and included patients aged 18 years and older.
AO-176 is a distinct investigational small molecule. No alternative names for this drug have been established in clinical research records.